522nd edition, August 23, 2022

Trouble Viewing This Email: Click Here

August 23, 2022

FOUNDING MEMBER OF

Maryland’s RoosterBio and Seattle’s AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies

SEATTLE, Aug. 16, 2022 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services.

The partnership creates an end-to-end solution for the development and production of hMSC and exosome therapeutics leveraging RoosterBio’s well-established cell and media products and process development services, coupled with AGC Biologics’ global cell and gene therapy manufacturing capabilities.

Biotech And Drug Development (Audio) – Bloomberg

Dr. Amrie Grammer, co-founder of AMPEL BioSolutions, joins the show to discuss biotech and her company Hosted by Paul Sweeney and Matt Miller.

Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older

If authorized, Novavax' vaccine would be the first protein-based COVID-19 booster for adults
If authorized, the Novavax COVID-19 Vaccine, Adjuvanted could be used as a booster dose for adults aged 18 and older vaccinated with any other currently available COVID-19 vaccine

GAITHERSBURG, Md., Aug. 15, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous and heterologous booster in adults aged 18 and older.

Biotechnology Investment Incentive Tax Credit (BIITC) Accepting 2023 Applications

The fiscal year 2022 program is now closed. The fiscal year 2023 program will begin accepting applications as follows: Commerce will begin accepting Form B QMBC applications on 8/23/2022, and Form A Investor applications on 9/7/2022. Additional information is available under the “Apply” section.

BIITC provides an investor with a refundable State income tax credit for an eligible investment in a Qualified Maryland Biotechnology Company (QMBC). The program supports investment in seed and early stage biotech companies to promote and grow the biotech industry in Maryland.

D.C. Area Life Sciences Market Down to 1.4% Vacancy – Commercial Observer

The Washington, D.C./Baltimore region continued to see a tightening in its life sciences real estate market.

In particular, the region saw a decrease in life sciences vacancy in the second quarter of 2022, dropping from 3.6 percent to 1.4 percent since last year, according to CBRE’s latest national life sciences report.

Image: THE RECENT DEAL FOR THE TWINBROOK OFFICE CENTER HIGHLIGHTS THE DEMAND FOR LIFE SCIENCES SPACE IN THE MARYLAND SUBURBS OF D.C. PHOTO: BY NEWMARK

8 new high priority funding opportunities

We just released 8 new high priority funding opportunities where your company can make a difference in meeting the needs of cancer patients… Please see the solicitation and join our webinar on August 24th….

Technical.ly: 2 new medtech startups will spin out of Johns Hopkins research fund grants

Two new medical startups, focusing on addressing vision loss and catheter-associated urinary tract infections (UTIs), are on the horizon thanks to the $200,000 in grants the research teams received from the Johns Hopkins University’s Louis B. Thalheimer Fund for Translational Research.

14 researchers applied to the Thalheimer Fund, which was created to provide seed funding for proof-of-concept and validation studies of inventions coming out of Hopkins. The awards from the fund range from $25,000 to $100,000.

“We are excited to have received strong applications for disruptive technologies with commercialization potential that can have a future impact on human health and well-being,” Nicole Snell, associate director of ventures at Johns Hopkins Technology Ventures’ (JHTV) FastForward accelerator, which helps university-affiliated founders commercialize their technologies, said in a statement.

Don’t get distracted over ARPA-H fight; let’s win the bigger prize | Maryland Daily Record

Congress has approved a new agency — the Advanced Research Projects Agency for Health (ARPA-H) — that will ‘supercharge’ breakthrough medical research and provide over $1 billion in new research funding.

A fight has broken out, however, over ARPA-H’s headquarters’ location. The Maryland congressional delegation is working to locate it in state, but when a majority in Congress senses a chance to put a prestigious scientific headquarters in their home districts, Maryland likely will not win this battle.

Leave a Reply Cancel Reply

About BioHealth Innovation

Contact

Connect